ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 813

Prevalence of Gastroesophageal Disease in Systemic Sclerosis and Its Impact on Lung Disease: Fact or Fiction

Tasneam Shagroni1, David Lin2, Jeremy Wang2, Isela Valera3, Aly M Aly4, Philip J. Clements2, Daniel E. Furst2, Rajan Saggar5, Jeffrey Conklin6 and Suzanne Kafaja2, 1Rheumatology, University of California Los Angeles, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, 4Alexandria University Faculty of Medicine, Alexandria, Egypt, 5UCLA, Los Angeles, CA, 6Medicine, University of California Los Angeles, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Gastrointestinal complications and systemic sclerosis, Lung Disease

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) patients frequently have upper gastrointestinal (GI) symptoms, with GI involvement being the leading cause of morbidity. Meanwhile, interstitial lung disease (ILD) and pulmonary hypertension (PH) are the leading cause of mortality in SSc. Reflux disease may play a role in ILD through chronic microaspiration and/or altered pulmonary mechanics in ILD can potentiate the impact of reflux. A potential causality between the two variables has yet to be established.

We investigated the prevalence of esophageal motility disorders and reflux in SSc patients and evaluated the relationship between GI characteristics and pulmonary outcomes.

Methods: This retrospective chart review was carried out at the University of California, Los Angeles (UCLA). Patients included in the study were diagnosed with systemic sclerosis and evaluated in SSc-GI clinic. Esophageal evaluation was carried out using at least one of the following modalities: high-resolution esophageal manometry (HREM), ambulatory pH testing and/or EGD. Data, collected within 1 year of the GI procedures, included: patient demographics, scleroderma characteristics, motility data, presence of ILD defined by HRCT, PH, oxygen requirement, and pulmonary function tests (PFTs) completed within one year of the index GI study. Statistical analyses included descriptive, ANOVA or Chi square testing as appropriate.

Results: Our study cohort included 122 patients, mean age± SD of 66± 9 at GI evaluation. 93% of patients were female, 68% had limited and 32% had diffuse cutaneous disease.

Most patients underwent HREM and EGD. Approximately 70% of the patients had absent contractility on manometry, while another 24% had ineffective esophageal motility. Hiatal hernia was found in one third of patients. Of those who underwent EGD, 37% had erosive esophagitis, while only 23% had a definitive diagnosis of GERD based on EGD. A portion of our cohort completed ambulatory pH testing, with 68% of studies demonstrating GERD. ILD was noted in 55% of patients.

We found no correlation between patient FEV1, FVC and/or DLCO and esophageal motility disorders based on HREM or the diagnosis of GERD based on EGD/pH studies. There were no significant differences in the PFTs and different HREM diagnoses, between patients with and without a diagnosis of GERD, or between patients with ILD with normal and abnormal motility. Our preliminary data did not reveal any correlation between esophagitis or hiatal hernia and ILD per HRCT findings.

Conclusion: Our study is one of the largest single-center cohorts of SSc patients characterizing esophageal motility, reflux and PFTs. The majority of our patients demonstrated abnormal motility, a finding believed to contribute to reflux. Over half of our cohort had lung involvement. There was no association found between esophageal dysmotility and/or GERD with PFTs. Similarly, preliminary data support a similar trend with HRCT findings of ILD. Given the lag time between discernable PFT changes and radiographic findings on HRCT, additional characterization of GI disease and early radiographic findings of ILD and PFT changes overtime is helpful and underway.


Disclosure: T. Shagroni, None; D. Lin, None; J. Wang, None; I. Valera, None; A. M. Aly, None; P. J. Clements, None; D. E. Furst, None; R. Saggar, None; J. Conklin, None; S. Kafaja, None.

To cite this abstract in AMA style:

Shagroni T, Lin D, Wang J, Valera I, Aly AM, Clements PJ, Furst DE, Saggar R, Conklin J, Kafaja S. Prevalence of Gastroesophageal Disease in Systemic Sclerosis and Its Impact on Lung Disease: Fact or Fiction [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-gastroesophageal-disease-in-systemic-sclerosis-and-its-impact-on-lung-disease-fact-or-fiction/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-gastroesophageal-disease-in-systemic-sclerosis-and-its-impact-on-lung-disease-fact-or-fiction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology